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Abstract 
Survivors of childhood cancer have a higher mortality than the general population. We describe 
cause-specific long-term mortality in a population-based cohort of childhood cancer survivors. We 
included all children diagnosed with cancer in Switzerland (1976-2007) at age 0-14 years, who 
survived ≥5 years after diagnosis and followed survivors until December 31, 2012. We obtained 
causes of death (COD) from the Swiss mortality statistics and used data from the Swiss general 
population to calculate age-, calendar year- and sex-standardized mortality ratios (SMR), and 
absolute excess risks (AER) for different COD, by Poisson regression. We included 3’965 survivors and 
49’704 person years at risk. Of these, 246 (6.2%) died, which was 11 times higher than expected 
(SMR 11.0). Mortality was particularly high for diseases of the respiratory (SMR 14.8) and circulatory 
system (SMR 12.7), and for second cancers (SMR 11.6). The pattern of cause-specific mortality 
differed by primary cancer diagnosis, and changed with time since diagnosis. In the first 10 years 
after 5-year survival, 78.9% of excess deaths were caused by recurrence of the original cancer (AER 
46.1). Twenty-five years after diagnosis, only 36.5% (AER 9.1) were caused by recurrence, 21.3% by 
second cancers (AER 5.3) and 33.3% by circulatory diseases (AER 8.3). Our study confirms an elevated 
mortality in survivors of childhood cancer for at least 30 years after diagnosis with an increased 
proportion of deaths caused by late toxicities of the treatment. The results underline the importance 
of clinical follow-up continuing years after the end of treatment for childhood cancer.  
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Introduction 
Cancer is the second most common cause of death in children in developed countries.
1,2
 
Improvements in childhood cancer therapies have drastically increased survival over the past 
decades, and 5-year survival rates now exceed 80%.
3–6
 Unfortunately, about two thirds of childhood 
cancer survivors experience late effects from the cancer or its treatment; about a third of these 
effects are severe or life threatening.
7,8
 The leading causes of death for children who have survived 5-
years after diagnosis are recurrence or progress of the original tumour, second cancers, and non-
neoplastic diseases, for example, of the circulatory or respiratory system.
9–13
 Clinical studies are 
generally designed for assessing efficacy of treatment protocols typically up to 5 up or 10 years from 
diagnosis. Several studies have shown that survivors of childhood cancer are not followed 
systematically into adulthood.
14,15
 Epidemiological studies are therefore necessary to monitor long-
term mortality on the population level. Although there are studies on cause-specific long-term 
mortality at the population level in the US, and in Europe,
10,11,16–25
 few could include recently 
diagnosed children
9,12
. As treatment modalities have changed over the past decades, studies should 
include younger cohorts of survivors who have benefited from newer treatment regimens.
26
  
We used data from the Swiss Childhood Cancer Registry (SCCR) i) to compare overall and cause-
specific mortality of childhood cancer survivors to that of the general population in Switzerland and 
describe associated factors, and ii) describe cumulative mortality after 5-year survival for different 
causes of death and different diagnostic periods. 
 
Methods 
Patient cohort 
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The study cohort consisted of all 5-year survivors of childhood cancer diagnosed before age 15 
between January 1, 1976 and December 31, 2007 in Switzerland. Data came from the population-
based Swiss Childhood Cancer Registry (SCCR).
27,28
 Recent estimates suggest that it includes 91%  
(about 95% since 1995) of all childhood cancer cases diagnosed in Switzerland.
29
 The SCCR has access 
to medical records of patients and codes the primary cancer diagnosis in childhood according to the 
International Classification of Childhood Cancer (ICCC), 3rd edition.
30
 
Ascertaining cause of death 
We obtained coded causes of death by linking records with mortality statistics in Switzerland.
31
 The 
COD statistics always includes the underlying COD and, if available, one consecutive, and up to two 
contributing causes of death, as coded by the Swiss Federal Statistical Office (SFSO). SFSO coded 
causes of death according to the International Classification of Diseases, 8
th
 revision (ICD-8) for 
deaths before 1995, and according to the 10
th
 revision (ICD-10) for deaths after 1995.
32,33
 For each 
death, we asked the SFSO for a copy of the original death certificate. Death certificates also contain 
notes and remarks about a death, which are not always possible to be classified by the ICD of the 
corresponding period. Medical personnel of the SCCR had information on date, site, morphology, 
treatment and recurrence/progression of the original cancer diagnosis, and examined death 
certificates. The most probable cause of death from a clinical point of view was assessed and 
compared with the officially underlying cause of death from mortality statistics. If the clinical cause 
of death was different from the official cause of death, we used the clinical cause of death, and 
coded it based on the ICD of the corresponding period. Otherwise we used the official cause of death 
and its ICD code. We classified coded cause of death into the following subgroups: recurrence or 
progression of the primary cancer; second cancers; circulatory diseases; respiratory diseases; 
infectious and parasitic diseases; other medical causes of death; and, external causes of death.  
Statistical methods 
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Examination of long-term mortality for all cohort members started 5 years after their first childhood 
cancer was diagnosed and continued until date of death, loss-to-follow-up, or December 31, 2012, 
whichever came first. We calculated standardized mortality ratios (SMR) and absolute excess risks 
(AER) overall and for specific causes of death. SMR and AER were age- (1-year band), calendar year 
(1-year band)- and sex-standardized using Swiss mortality rates as obtained from the SFSO. SMR was 
defined as the ratio of observed deaths divided by the number of expected deaths. AER was defined 
as the observed number of deaths minus the expected number of deaths, divided by the number of 
person-years at risk, and expressed by 10,000 person-years. Because there are no deaths from 
recurrence the general population, we only report crude mortality rates for this cause of death. We 
stratified SMR and AER by sex, age at diagnosis (<1 year, 1-4, 5-9 and 10-14 years), type of childhood 
cancer (ICCC-3 main groups), recurrence within 5 years from diagnosis (no/yes), radiotherapy 
(no/yes), chemotherapy (no/yes), HSCT (no/autologous/allogeneic) and years from diagnosis of the 
primary childhood cancer (5-14, 15-24, ≥24). For the all causes combined we further stratified ICCC-3 
main groups into subgroups (acute lymphatic leukaemia (ALL), acute myeloid leukaemia (AML), 
Hodgkin- and non-Hodgkin lymphoma, ependymomas, astrocytomas, primitive neuroectodermal 
tumors (PNET), medulloblastomas, osteosarcomas, Ewing sarcomas, rhabdomyosarcomas and other 
soft-tissue sarcomas). If data for a variable was missing, we grouped the missing values in an 
additional category. We estimated the simultaneous effect of these factors on risk of death from all 
causes of death, from recurrence and from second cancers using multivariable Poisson regression 
models that included all variables and were adjusted for era of treatment (1976-1983, 1984-1991, 
1992-1999, 2000-2007). We estimated cumulative mortality (CM) as a function of time since 
diagnosis for different causes of death and different diagnostic periods. We used logrank test for 
trend to test for trends in CM and treated causes of death, other than the one under observation, as 
competing risks using the “stcompet” command in STATA. Between 1976 and 1981, the SCCR mainly 
registered children who were included in clinical studies. We assume that certain tumors, especially 
those not treated in a specialized pediatric cancer center, were not registered in the SCCR. In a 
sensitivity analysis, we repeated our main analysis of overall SMR considering only cases diagnosed 
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1985-2007. P-values were two sided; we considered a p-value of ≤0.05 to be statistically significant. 
STATA, version 13 was used for all statistical analyses (StataCorp. 2013. Stata Statistical Software: 
Release 13.1.College Station, TX: StataCorp LP). 
Results 
Cohort characteristics 
Of 5,190 children diagnosed with cancer in Switzerland between 1976 and 2007, 3,965 (76%) were 
long-term survivors for 5 years or more. By the study exit date, 246 (6.2%) of them had died, 113 
(2.9%) were lost-to-follow-up, and 3,606 (91.0%) were still alive. COD was available for 226 (92.0%) 
of the deceased. In 23 of 226 cases (10.2%), handwritten information on the death certificate or the 
patients’ medical history caused us to recode the official COD from primary cancer to a second 
cancer (N=13), or a non-cancer late fatality (n=10). We included 49’704 person-years at risk from 5-
year survival. Mean follow-up time was 17.5 (95% confidence interval [CI] 17.3-17.8) years from 
diagnosis; median was 16.5 years (range 5.0 to 36.9). Information on radiotherapy was missing for 
303 patients (7.6%), on chemotherapy for 251 patients (7.6%), and on HSCT for 330 patients (8.3%).  
 
Overall mortality 
Survivors were 11 times more likely to die than their peers in the general population (SMR 11.0). 
There were 45 extra deaths (AER 45.0) per 10’000 person-years (Table 1). SMR was higher in females 
(SMR 18.4) than males (SMR 8.5), while the AER was comparable. The SMR was higher in children 
diagnosed at ages <1 year (SMR 14.3) and 1-4 years (SMR 15.4) than in those diagnosed at ages 5-9 
(SMR 11.2) and 10-14 (SMR 7.5). Those who had had recurrent disease within 5 years of diagnosis 
were likely to have considerably higher mortality from any cause (SMR 43.7) than those without 
recurrence during that period (SMR 6.8). Children who had autologous (SMR 65.6) or allogeneic HSCT 
(SMR 48.5) in the first 5 years after diagnosis had significantly higher SMR compared to those 
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without HSCT (SMR 9.9). The SMR declined with increasing follow-up time and attained age (p<0.001 
for trend). However, significant excess mortality remained beyond 24 years from diagnosis (SMR 5.6). 
Number of excess deaths was largest during the first 10 years after 5-year survival (AER  62.2), 
declined thereafter between 15 and 24 years after diagnosis (AER 14.4) and increased again beyond 
24 years after diagnosis (AER 31.5). We observed the greatest SMRs among survivors of 
ependymoma (SMR 36.8), AML (SMR 28.2), medulloblastoma (SMR 25.9) and Ewing sarcoma (25.8). 
AER varied widely by primary cancer diagnosis and was largest for those diagnosed with 
ependymoma (AER 155.7), Ewing sarcoma (AER 119.5) and AML (AER 109.7). In regard of ICCC-3 
main group, the SMR was highest for children diagnosed with neuroblastoma (SMR 18.9), CNS 
tumours (SMR 15.7), leukaemia (SMR 15.1) and bone tumours (SMR 14.2). AER was largest for bone 
tumours (AER 74.8), CNS tumours (AER 63.9), leukaemia (AER 60.1) and neuroblastoma (AER 51.7). 
 
Cause-specific mortality 
SMRs were significantly elevated for deaths from second cancers (SMR 11.6), diseases of the 
circulatory system (SMR 12.7), diseases of the respiratory system (SMR 14.8) and infectious diseases 
(SMR 7.3) (Table 2). Mortality was not increased for deaths due to other medical causes (SMR 0.9) 
and external causes (SMR 1.0). Highest number of excess deaths was observed for deaths due to 
recurrence or progression of the original cancer (AER 30.9), second cancer (AER 5.9) and circulatory 
disease (AER 2.9). For diseases of the respiratory system, and infectious diseases, AERs were <1 per 
10’000 person-years.  
We then proceeded to determine potential explanatory factors for all cause mortality, recurrence, 
second cancers and circulatory diseases. To do this, we stratified SMR and AER by different 
explanatory factors. Crude mortality rate for recurrence or progression of the original cancer, which 
can be interpreted as an AER, was highest in survivors of CNS tumours (AER 54.9) and bone tumours 
(AER 54.8) (Table 1). Number of excess deaths due to recurrence was highest at 5 to 14 years from 
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diagnosis (AER 46.1) and declined to below 10 excess deaths beyond 14 years from diagnosis. 
Multivariable analysis showed that children who suffered from recurrent disease during the first 5 
years after diagnosis were at higher risk of death due to recurrence or progression (RR 8.2) than 
those without recurrence (Table 4). Children treated with radiotherapy (RR 2.2), chemo therapy (RR 
4.4), or autologous HSCT (RR 3.7) in the first 5 years after diagnosis were more likely to die from 
recurrence than those who did not receive radiotherapy, chemotherapy or HSCT.  
SMR for second cancers was highest for children originally diagnosed with retinoblastoma (SMR 47.2) 
and leukaemia (SMR 18.6) (Table 1). Mortality due to second cancers was relatively stable over 
follow-up time with 6.6 excess deaths at 5-14 years after diagnosis, 4.7 at 15-24 years and 5.3 excess 
deaths beyond 24 years from diagnosis. Multivariable analysis showed that children treated with 
radiotherapy (RR 9.2), allogeneic HSCT (RR 12.5) or autologous HSCT (RR 6.3) had a higher risk for 
death due to second primary cancer than those without radiotherapy or HSCT (Table 4). Those who 
had had recurrent disease within the first 5 years after diagnosis had the same risk for mortality due 
to second cancers as those who did not have recurrence.   
From 5-14 years after diagnosis, recurrence accounted for 78.9% of all excess deaths, second cancers 
for 11.3%, circulatory diseases for 4.9% and all other causes of death for 2.9% (Table 3). Beyond 24 
years after diagnosis the proportion decreased to 36.5% for recurrence, but increased to 21.3% for 
second cancers, to 33.3% for circulatory diseases and to 8.9% for all other causes of death. 
 
Cumulative mortality  
Cumulative mortality (CM), which can be interpreted as a probability of death, was 8.8% (CI 6.4-15.0) 
at 30 years after diagnosis for all 5-year survivors (Figure 1). The CM for death from recurrence or 
progression increased steeply with time from diagnosis, to 3.3% (CI 2.8-4.0) at 10 years. It then 
increased at a slower pace, to 5.2% (CI 4.3-6.3) at 30 years from diagnosis. The CM for all causes 
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except recurrence was 10.8% (CI 0.6-1.2) at 10 years from diagnosis, but increased continuously to 
3.5% (CI 2.6-4.6) at 30 years from diagnosis.  
CM decreased significantly with time of diagnosis for 5-year survivors of childhood cancer (Figure 2). 
The probability of dying from all causes of death combined within the next 5 years dropped most 
markedly between the periods 1976-1983 (9.0%, CI 6.9-11.6) and 1984-1993 (3.9%, CI 1.7-3.8). CM at 
10 years after diagnosis did not differ significantly between later periods due to low numbers. But we 
observed an on-going trend for decreasing CM when looking at the total follow-up time of all 4 
periods (p-trend<0.001).  
 
Sensitivity analysis  
We further performed a sensitivity analysis by considering only cases diagnosed since 1985. Results 
did not materially change: the overall SMR was 11.4 (CI 9.7-13.4) and the AER 38.6 (CI 32.5-45.9). 
Discussion 
This population-based cohort of 5-year survivors of childhood cancer showed that this group of 
patients remains at significantly increased risk for death 30 years after diagnosis. At 5-14 years after 
diagnosis, 79% of all extra deaths were caused by recurrence of the primary cancer, but this 
proportion decreased to 37% ≥24 years from diagnosis. In contrast, the proportion of extra deaths 
from second cancers, circulatory diseases, respiratory diseases and other diseases increased steadily 
with time from diagnosis and accounted for 64% of all deaths occurring beyond 24 from diagnosis. 
Cumulative mortality beyond 5 years after diagnosis decreased significantly over time.  
 
The SMR estimated in our study was consistent with results from the British Childhood Cancer 
Survivor study (BCCSS) (SMR 10.7), and was somewhat higher than had been reported from the 
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Childhood Cancer Survivor study (CCSS) (SMR 8.4) and the Nordic countries (SMR 8.3).
10,11,20
 A study 
from Scotland, similar in size to our own, analysed long-term cause-specific mortality among 
children, adolescents, and young adults with cancer; this study reported an overall SMR for 
childhood cancer (age at diagnosis 0-14 years) of 11.0 similar to ours, but found a slightly higher 
number of AER (51).
12
 Similar to our study, the CCSS reported highest SMRs among survivors of 
Ewing sarcomas and medulloblastomas or PNET. However, the CCSS did not differentiate between 
PNET and medulloblastomsa.
20
 In contrast the CCSS found a lower SMR for AML (SMR 9.5) compared 
to our study. In terms of ICCC-3 main groups, the high overall SMR for leukaemia and CNS tumours 
(SMR > 15) estimated in our study were comparable to findings from other studies.
11,12,20
 However 
most other studies reported a lower overall SMR for neuroblastomas. In our study SMR for deaths 
due to diseases of the respiratory system, circulatory system and second cancer was largest (SMR > 
10). This was slightly higher than reported in the BCCSS (for all 3 causes of death) and in the Nordic 
study (for circulatory diseases and second cancers).
11,24
 Similar to our study SMR was highest for 
diseases of the respiratory system (SMR 34.9) as reported in a study from the Nordic countries.
10
 In 
our study, mortality from external causes (including suicide) was not elevated, in contrast to the 
BCCSS.
11
 It is important to note, that there is some heterogeneity regarding age at diagnosis of the 
primary cancer, calendar period of diagnosis and length of follow-up in comparing studies. The 
decrease of AER for deaths due to recurrence and simultaneous increase of AER to other causes of 
death over study time was consistent with findings from the BCCSS, although it has a longer period of 
follow-up.
11
 Other studies did not compare cause specific SMR or AER at different times since 
diagnosis.  Crude mortality rates for recurrence deaths estimated in our study were highest for CNS 
tumours bone tumours and leukaemia. This is comparable to results form the BCCSS, which reported 
crude rates for recurrence deaths to be highest for PNET, leukaemia (excluding ALL), CNS tumours 
(excluding PNET) and bone tumours.
11
 Most other studies did not report crude rates for deaths due 
to recurrence for underling cancer diagnosis. Like in our study, the BCCSS reported high SMR for 
second cancers for children diagnosed with retinoblastoma. However, we were not able to 
distinguish between heritable and non-heritable retinoblastoma and we assume that the heritable 
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form of the disease drove the high SMR for retinoblastoma rather than treatment related causes. 
Like our study, studies from US, UK and the Nordic countries showed that CM from recurrence 
increased during the first 10 years from diagnosis, and then levelled off, while CM for second cancers 
and circulatory diseases, increased continuously with follow-up time. In 2012 Garwicz et al. explored 
temporal trends in CM using data from the Nordic countries.
10
 Similar to our study the most marked 
decrease in CM was observed for patients diagnosed during the 1980s compared to those diagnosed 
during the 1970s. However, the decrease in cumulative mortality from the first to the subsequent 
diagnostic period be interpreted cautiously. As commonly is the case in cancer registration, 
completeness of the SCCR was somewhat lower in its early years compared to today. Because the 
SCCR started as a clinical registry and registered mostly children enrolled in clinical studies, we 
assume that certain cancers were not registered completely, especially low grade CNS tumours and 
melanomas. The cumulative mortality observed for children diagnosed 1976-1984 may therefore 
have been overestimated. However, a sensitivity analysis showed that overall estimates of all cause 
SMR and AER did not change substantially when excluding the first period from the analysis (1976-
1984).   
 
Excess mortality due to second cancers, circulatory diseases and diseases of the respiratory system 
are likely caused by late effects of cancer treatment.
13,35–39
 Second cancers are widely accepted as a 
late effect of radiotherapy during the treatment, but also specific chemotherapeutic agents might be 
involved in the development of second cancers. Some second cancers might also be attributable to 
familial cancer syndromes like heritable retinoblastoma and Li-Fraumeni syndrome.
40–42
 Thus, the 
elevated SMR for second cancers in children diagnosed with retinoblastoma is a combination of 
treatment related late toxicities and genetic predisposition. Circulatory diseases may also be a late 
complication of childhood cancer therapy, primarily related to chest radiation or anthracyclines. 
Similar to the BCCSS and the CCSS cohort, we have also demonstrated adverse respiratory late 
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effects among childhood cancer survivors. However, this should be interpreted cautiously in the 
context of this rare disease with only 4 (1.8%) out of 226 late deaths attributable to it.  
 
One of the main advantages of this study was the combination of 3 resources. First, information on 
original childhood cancer diagnosis came from the population based SCCR. The SCCR is very complete 
(>95% since 1995) and it its not susceptible to response bias compared to questionnaire-based 
studies.  Second, clinical data such as information on treatment and follow-up was reported directly 
from the 9 specialized paediatric oncology clinics throughout Switzerland. We had access to most 
medical records and could validate treatment and follow-up data. Third, we had access to official 
death certificates and were able to validate code causes of death from official mortality statistics. 
This is important since it has been shown that deaths attributable to recurrence of the primary 
cancer can be overestimated, and consecutive or contributing causes of death (which might reflect 
therapy induced late effects) can be underestimated.
24,43
 Another advantage of our study was that 
we were able to include recently diagnosed patients (up to 2007), which many other studies could 
not do.
11,18,20
 But, our study was smaller than other studies, so we had limited capacity to perform 
subgroup analyses. Another limitation of our study was the lack of detailed data on radiotherapy and 
chemotherapy exposures and lack of data on applied dosages. Therefore, we were no able to analyse 
the effect of dose-response patterns on risk of morality. We validated COD of childhood cancer 
survivors, since cancer deaths were most probably overestimated. We must assume that this was 
also true for cancer deaths in the official statistics. If true, this would have led to an overestimation 
of expected deaths due to (second) cancer in our analysis and thus to an underestimation of 2nd 
cancer specific SMR. The form of the death certificate changed over the study period. However, data 
items concerning causes of death remained unchanged. Further, there has been a change in the 
coding system in the mortality statistics in Switzerland from ICD-8 to ICD-10 and an adaption of 
coding rules, which could introduce breaks into time series of disease coding. However, since we 
classified COD into broad categories, we assume that this break in the coding system and rules did 
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not affect the results of our study.  Deaths due to late effects of the treatment may have declined 
over time due to better follow-up care. If late effects become less fatal, mortality may become a less 
reliable indicator of the incidence of these late effects. This suggests that future studies should also 
address morbidity, not only mortality. 
 
Clinicians and patients need information on long-term outcomes, and especially mortality, to make 
sound decisions about treatment and follow-up. We demonstrated the usefulness of linking baseline 
cancer registry data and clinical data on treatment to routinely collected mortality records to 
monitor fatal late-effects inexpensively. Our results underline the importance of follow-up programs 
lasting years after the end of treatment for childhood cancer, and we suggest the use of standardized 
risk-adapted protocols for monitoring health conditions in the growing population of childhood 
cancer survivors. In absolute numbers, second cancers and circulatory disease account for most 
excess deaths in survivors diagnosed over 24 years ago, but this population is also less likely to 
attend follow-up than those were more recently diagnosed.
44
 Our results underline the importance 
of follow-up programs lasting years after the end of treatment for childhood cancer, and we suggest 
a standardized protocol would be useful for detailed monitoring of health conditions in detail in the 
growing population of childhood cancer survivors.  
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Table 1. Life status, standardized mortality ratios (SMR) and absolute excess risks (AER) for 5-year survivors of childhood cancer diagnosed at age 0-14 years between 1976 and 2007 (SMR and AER 
are standardized according to age-, sex- and calendar year) 
    All causes of death   
 
  
Recurrent/progressive disease 
1
 
 
  2nd cancer 
1
   
    
Eligible 
Cohort PY Obs/Exp SMR AER
2
   Obs Crude rate 
2
   Obs/Exp SMR AER
2
 
All patients  3965 49703.9 246/22.3 11.0 (9.7-12.5) 45.0 (39.6-52) 
 
153 30.9 (26.4-36.2) 
 
32/2.8 11.6 (8.2-16.4) 5.9 (4-8.5) 
Sex 
            
 
Male 2215 27838.6 142/16.7 8.5 (7.2-10) 45 (37.9-54.8) 
 
87 31.3 (25.4-38.7) 
 
18/1.6 11 (6.9-17.4) 5.9 (3.5-9.7) 
 
Female 1750 21865.4 104/5.6 18.4 (15.2-22.4) 45 (36.8-55.2) 
 
66 30.3 (23.8-38.6) 
 
14/1.1 12.5 (7.4-21) 5.9 (3.3-10.4) 
Age at diagnosis, years 
            
 
<1  379 4582.4 17/1.2 14.3 (8.9-23) 34.5 (21.6-58.3) 
 
8 17.5 (8.7-34.9) 
 
4/0.2 24.1 (9-64.1) 8.4 (3.1-23.3) 
 
1-4 1405 17988.8 89/5.8 15.4 (12.5-18.9) 46.3 (37.8-58.5) 
 
60 33.4 (25.9-43) 
 
14/0.7 19.3 (11.4-32.6) 7.4 (4.3-12.9) 
 
5-9 1076 13802.3 75/6.7 11.2 (8.9-14) 49.5 (39.2-64.0) 
 
50 36.4 (27.6-48.1) 
 
8/0.8 10.4 (5.2-20.9) 5.3 (2.3-11.2) 
 
10-14 1103 13330.4 65/8.6 7.5 (5.9-9.6) 42.3 (31.3-55.2) 
 
35 26.5 (19-36.9) 
 
6/1.1 5.5 (2.5-12.1) 3.7 (1-9.8) 
Treatment era 
 1976 - 1983 577 13970.7 98/9.4 10.4 (8.6-12.7) 63.4 (51.3-79.3) 57 41.1 (31.7-53.3) 15/1.2 12.2 (7.4-20.3) 9.9 (5.7-17.2) 
 
1984 - 1991 901 17017.5 61/7.8 7.8 (6.1-10) 31.2 (24.2-42.4) 
 
31 18.2 (12.8-25.9) 
 
9/0.9 10.1 (5.2-19.4) 4.8 (2.3-9.8) 
 
1992 - 1999 1182 13624.2 58/4.1 14.1 (10.9-18.2) 39.5 (30.7-52.9) 
 
44 32.4 (24.1-43.5) 
 
5/0.5 10.2 (4.3-24.6) 3.3 (1.3-8.8) 
2000 - 2007 1305 5091.5 29/1 28.7 (19.9-41.3) 55 (37.8-80.2) 21 41.3 (26.9-63.4) 3/0.2 19.3 (6.2-59.9) 5.6 (1.7-18.4) 
Recurrence 
            No 3496 44475.6 134/19.8 6.8 (5.7-8) 25.4 (20.8-31) 
 
66 14.9 (11.7-19) 
 
24/2.5 9.8 (6.5-14.6) 4.7 (3-7.5) 
Yes 469 5228.3 112/2.6 43.7 (36.3-52.6) 210.9 (174.7-254.5) 86 165.2 (133.8-204.1) 8/0.3 26.5 (13.3-53) 14.9 (7.3-30.4) 
Radiotherapy 
            No 2411 28367.2 74/10.9 6.8 (5.4-8.5) 22.3 (17.1-29.1) 
 
48 17 (12.8-22.5) 
 
4/1.4 3 (1.1-7.9) 0.9 (0.2-4.1) 
Yes 1251 17590.6 159/9.5 16.8 (14.4-19.6) 86.1 (73.1-101.3) 99 56.4 (46.4-68.7) 26/1.2 22.4 (15.3-32.9) 14.2 (9.4-21.1) 
 
Unknown 303 3474.1 13/1.9 6.7 (3.9-11.6) 30.2 (16.2-56.2) 
 
6 16.1 (7.2-35.9) 
 
2/0.3 8 (2-31.8) 5.1 (1.2-22) 
Chemotherapy 
 No 733 8560.5 15/3.6 4.2 (2.5-6.9) 14.2 (7.7-26.3) 9 10.5 (5.5-20.3) 0/0.5 NA NA 
 
Yes 2981 37644.3 218/16.9 12.9 (11.3-14.8) 53.7 (46.6-62) 
 
138 36.8 (31.1-43.5) 
 
30/2.1 14.5 (10.2-20.8) 7.4 (5-10.8) 
 
Unknown 251 3499.1 13/1.9 6.9 (4-12) 32.6 (17.6-60.4) 
 
6 17.3 (7.8-38.4) 
 
2/0.2 8.2 (2.1-32.9) 5.5 (1.3-23.6) 
Transplantation 
 
No 3467 44119.1 194/19.6 9.9 (8.6-11.4) 39.8 (34.1-46.5) 
 
123 28 (23.4-33.4) 
 
20/2.4 8.3 (5.3-12.8) 3.9 (2.3-6.4) 
 
Allogeneic 94 938 20/0.4 48.5 (31.3-75.2) 208.9 (133.5-326.7) 
 
9 98.2 (51.1-188.7) 
 
7/0 147.8 (70.5-310.1) 75.8 (36-159.9) 
Autologous 74 617.7 16/0.2 65.6 (40.2-107.1) 256.4 (156.3-420.6) 13 210.5 (122.2-362.4) 2/0 72.8 (18.2-291.1) 31.9 (7.8-130.3) 
 
Unknown 330 4029.2 16/2.1 7.6 (4.7-12.4) 34.4 (19.6-60.4) 
 
7 17.5 (8.3-36.7) 
 
3/0.3 10.9 (3.5-34) 7.1 (2.2-23.5) 
Years from cancer 
diagnosis, years 
            5-14 3965 30247.2 199/10.9 18.3 (15.9-21) 62.2 (53.9-72.2) 
 
139 46.1 (39.1-54.5) 
 
21/1.2 18.2 (11.8-27.9) 6.6 (4.2-10.4) 
 
15-24 2203 15034.2 30/8.4 3.6 (2.5-5.1) 14.4 (8.4-23.1) 
 
10 6.7 (3.6-12.4) 
 
8/0.9 8.6 (4.3-17.1) 4.7 (2-10.2) 
  ≥ 25 882 4422.5 17/3.1 5.6 (3.5-8.9) 31.5 (15-53.8)   4 9.1 (1.1-2750.6)   3/0.7 4.5 (1.4-13.9) 5.3 (0.8-24.7) 
Attained age, years             
 0-19 1462 7232.7 174/1.1 161.8 (139.5-187.8) 239.1 (204.5-276.2)  124 172.1 (144.3-205.2)  21/0.2 97.2 (63.4-149.0) 28.8 (18.7-44.4) 
 20-29 1390 17184.5 48/5.6 8.6 (6.5-11.4) 24.7 (14.0-30.9)  24 14.0 (9.4-20.9)  5/0.6 8.2 (3.4-19.7) 2.6 (0.7-7.0) 
 30-39 856 18303.8 13/9.6 1.4 (0.8-2.3) 1.9 (0.0-34.1)  2 1.1 (0.3-4.4)  4/1.1 3.7 (1.4-9.9) 1.6 (0.1-9.3) 
 40-49 254 6889.6 11/6 1.8 (1.0-3.3) 7.3 (0.7-32.9)  3 4.4 (1.4-13.6)  2/0.8 2.4 (0.6-9.5) 1.7 (0.0-110.2) 
 ≥50 3 93.4 0/0.1 NA NA  0 NA  0/0 NA NA 
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Table 1. Life status, standardized mortality ratios (SMR) and absolute excess risks (AER) for 5-year survivors of childhood cancer diagnosed at age 0-14 years between 1976 and 2007 (SMR and AER are 
standardized according to age-, sex- and calendar year) (continued) 
   
    All causes of death 
 
  
Recurrent/progressive disease 
1
 
 
  Second cancer 
1
 
    
Eligible 
Cohort PY Obs/Exp SMR AER
1
   Obs Crude rate   Obs/Exp SMR AER
1
 
Childhood cancer diagnosis 
5
 
           
 
I. Leukaemia 1289 16464.3 106/7.0 15.1 (12.5-18.2) 60.1 (49.2-73.8) 
 
68 41.5 (32.7-52.7) 
 
16/0.9 18.6 (11.4-30.4) 9.2 (5.4-15.4) 
    Ia.  ALL 576 14908.2 86/6.4 13.4 (10.9-16.6) 53.7 (42.8-67.4) 
       
  Ib. AML 679 1222.1 14/0.5 28.2 (16.7-47.5) 109.7 (63.5-189.5) 
II. Lymphoma 576 7893.8 25/5.0 5.0 (3.4-7.4) 25.3 (14.3-40) 8 10.2 (5.1-20.4) 5/0.6 8.3 (3.5-20.0) 5.6 (1.7-15.1) 
 
  IIa. Hodgkin lymphoma 237 3251.6 16/2.2 7.3 (4.5-11.9) 39.8 (21.8-72.8) 
       
 
  IIb. Non-Hodgkin lymphoma 191 2640.6 8/1.7 4.7 (2.3-9.3) 25.0 (10.9-57.7) 
       
 
III. CNS tumours 679 692.5 51/3.3 15.7 (11.9-20.6) 63.9 (48.6-86.5) 
 
41 54.9 (40.4-74.6) 
 
3/0.4 7.4 (2.4-23.0) 3.5 (1.1-12.6) 
 
  IIIa. Ependymoma 62 692.5 11/0.3 36.8 (20.4-66.5) 155.7 (85.3-284.5) 
       
 
  IIIb. Astrocytoma 294 3104.6 15/1.2 12.5 (7.5-20.7) 45.9 (27-78.2) 
       
 
  IIIc. PNET 22 205.0 1/0.1 15.3 (2.2-108.4) 44.5 (5.2-381.9) 
       
 
  IIIc. Medulloblastoma 109 1319.1 17/0.7 25.9 (16.1-41.7) 123.5 (75.2-202.7) 
       
 
IV. Neuroblastoma 218 2749.4 15/0.8 18.9 (11.4-31.3) 51.7 (31.2-88.9) 
 
10 36.4 (19.6-67.6) 
 
1/0.1 9.5 (1.3-67.2) 3.3 (0.4-28.5) 
 
V. Retinoblastoma 131 1733.1 4/0.5 8.3 (3.1-22.1) 20.3 (6.3-61.7) 
 
0 NA 
 
3/0.1 47.2 (15.2-146.5) 
16.9 (5.3-
53.9) 
 
VI. Renal tumours 235 3056.4 6/0.9 6.8 (3.1-15.2) 16.8 (7.5-43.1) 
 
3 9.8 (3.2-30.5) 
 
2/0.1 16.6 (4.2-66.4) 6.2 (1.5-26.7) 
 
VII. Hepatic tumour 28 328.2 1/0.1 9.0 (1.3-63.6) 27.1 (3.9-224.2) 
 
1 30.5 (4.3-216.3) 
 
0/0.0 NA NA 
VIII. Bone tumours 159 1863.2 15/1.1 14.2 (8.6-23.6) 74.8 (43.4-128.9) 10 54.8 (29.5-101.9) 1/0.1 7.8 (1.1-55.3) 4.8 (0.5-46.9) 
  VIIIa. Osteosarcoma 74 888.8 5/0.5 9.1 (3.8-22) 51.0 (19.5-133.9) 
 
  VIIIc. Ewing sarcoma 77 796.5 10/0.4 25.8 (13.9-47.9) 119.5 (62.4-229.1) 
       
 
IX. Soft-tissue sarcomas 244 3130.0 16/1.5 10.3 (6.3-16.9) 46.2 (27.7-80.0) 
 
10 32.0 (17.2-59.4) 
 
1/0.2 5.3 (0.7-37.4) 2.6 (0.3-25.2) 
 
  IXa. Rhabdomyosarcoma 137 1750.7 7/0.8 8.9 (4.2-18.6) 35.7 (15.6-81.5) 
       
 
  IXd. Other soft-tissue sarcomas  105 1325.7 9/0.7 12.8 (6.7-24.6) 64.1 (32.1-127.9) 
       
 
X. Germ cell tumours 119 1548.0 1/0.6 1.6 (0.2-11.1) 2.3 (0.3-70.0) 
 
1 6.5 (0.9-45.9) 
 
0/0.1 NA NA 
  Other cancers 287 3467.8 6/1.5 3.9 (1.8-8.7) 12.9 (5.1-37.2)   1 2.9 (0.4-20.5)   0/0.2 NA NA 
1 
Subjects
 
with unknown causes of death were a priori excluded  
2 
Per 10’000 person-years at risk 
3
 Can be interpreted as an absolute excess risk 
4
 Second primary cancer 
5 
According to the International Classification of Childhood Cancer, 3
rd
 edition 
Abbreviations: PY = person-years, Obs = observed, Exp = expected, CI = confidence interval, NA = not applicable, ALL = acute lymphoblastic leukaemia, AML = acute myeloid leukaemia, CNS = central nervous system, PNET = 
primitive neuroectodermal tumours 
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Table 2. Observed and expected numbers of death, standardized mortality ratio (SMR) and 
absolute excess risk (AER) for specific causes of death 
    Obs/Exp SMR (95% CI) AER
1
 (95% CI) 
All causes of death 226/22.2 10.2 (8.9-11.6) 41.2 (36.1-48) 
 Recurrent/progressive disease 153/0.0 NA 30.9 (26.4-36.2) 
      All causes except recurrence 73/22.2 3.3 (2.6-4.1) 10.3 (7.2-13.8) 
 2nd cancer 32/2.8 11.6 (8.2-16.4) 5.9 (4.0-8.5) 
All causes except cancer 41/19.5 2.1 (1.6-2.9) 4.3 (2.1-7.2) 
 Diseases of the circulatory system 16/1.3 12.7 (7.8-20.7) 2.9 (1.5-4.7) 
 Diseases of the respiratory system 4/0.3 14.8 (5.6-39.4) 0.7 (0.3-2.2) 
 Infectious diseases 4/0.5 7.3 (2.7-19.4) 0.7 (0.2-2.2) 
 External causes  13/12.8 1 (0.6-1.8) 0.0 (0.0-7.4) 
  Other causes
2
 4/4.6 0.9 (0.3-2.3) NA 
1 
Per 10’000 person-years at risk 
2
 All other causes of death other than the ones mentioned above 
Abbreviations: Obs = observed, Exp = expected, CI = confidence interval 
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Table 3. Absolute excess risks (AER) by years from diagnosis as a 
proportion of total AER 
 
AER (% 
1
) by years from diagnosis 
Cause of death 5-14 15-24 >24 
Recurrent/progressive disease 46.1 (78.9) 6.7 (51) 9.1 (36.5) 
Second cancer 6.6 (11.3) 4.7 (36) 5.3 (21.3) 
Circulatory disease 2.8 (4.9) 1.7 (12.8) 8.3 (33.3) 
Other causes of death 2.9 (5) NA 2.2 (8.9) 
All deaths 
2
 58.4 13.1 24.9 
1 
Proportion of total AER during specific time period since diagnosis 
2  
Number of AER differs slightly from number indicated in table 1 due to unknown 
cause of death in 20 patients 
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Table 4. Risk ratios for death from different causes of death and 95% confidence intervals for different 
explanatory factors (adjusted for all variables shown)  
  
 
All causes of death    
 
 
Recurrent/progressive disease 
 
  Second cancer 
    Risk ratio (95% CI) p 
1
 
 
Risk ratio (95% CI) p 
1
 
 
Risk ratio (95% CI) P 
1
 
Sex  0.800   0.895    0.919 
 Male         
 Female 1.04 (0.78-1.38)   1.02 (0.74-1.42)   1.04 (0.48-2.26)  
Age at diagnosis, years  0.958   0.974   0.285 
 <1  1.14 (0.63-2.09)   0.85 (0.39-1.87)   2.36 (0.57-9.79)  
 1-4 1   1   NA  
 5-9 0.97 (0.69-1.37)   1.05 (0.71-1.55)   0.55 (0.2-1.49)  
 10-14 1.09 (0.73-1.62)   1.1 (0.7-1.73)   0.36 (0.1-1.26)  
Treatment era  <0.001   0.001   0.287 
 1976 - 1983 1   1   1  
 1984 - 1991 0.55 (0.37-0.8)   0.44 (0.28-0.7)   0.72 (0.27-1.95)  
 1992 - 1999 0.47 (0.32-0.68)   0.48 (0.31-0.74)   0.34 (0.11-1.07)  
 2000 - 2007 0.55 (0.34-0.89)   0.5 (0.29-0.86)   0.63 (0.16-2.54)  
Childhood cancer 
diagnosis
2
 
 <0.001   <0.001   0.851 
 I Leukaemia 1   1   1  
 II Lymphoma 0.32 (0.16-0.65)   0.27 (0.13-0.58)   0.77 (0.18-3.17)  
 III CNS tumours 1.96 (1.28-3)   2.29 (1.44-3.65)   1.16 (0.28-4.8)  
 IV Neuroblastoma 1.12 (0.59-2.14)   1.14 (0.53-2.44)   0.39 (0.04-3.77)  
 V Retinoblastoma 0.52 (0.15-1.81)   NA   1.73 (0.33-9.02)  
 VI Renal tumours 0.42 (0.17-1.07)   0.35 (0.11-1.13)   1.04 (0.21-5.2)  
 VII Hepatic tumour 1.15 (0.15-8.69)   1.76 (0.23-13.33)   NA  
 VIII Bone tumours 1.56 (0.82-2.98)   1.67 (0.82-3.38)   1.56 (0.17-14.58)  
 IX Soft-tissue sarcomas 1.03 (0.57-1.88)   1.07 (0.53-2.13)   0.51 (0.06-4.33)  
 X Germ cell tumours 0.14 (0.02-1.19)   0.22 (0.03-1.65)   NA  
 Other cancers 0.55 (0.21-1.44)   0.15 (0.02-1.1)   NA  
Recurrence  <0.001   <0.001   0.682 
 No 1   1   1  
 Yes 6.05 (4.47-8.21)   8.19 (5.81-11.55)   0.81 (0.3-2.22)  
Radiotherapy  <0.001   0.005   0.002 
 No 1      1  
 Yes 2.22 (1.58-3.13)   1.84 (1.26-2.68)   9.24 (2.58-33.15)  
 Unknown 0.5 (0.03-8.32)   0.57 (0.01-30.35)   0.53 (0-1284.82)  
Chemotherapy  <0.001   <0.001   0.093 
 No 1   1   1  
 Yes 4.42 (2.11-9.28)   4.3 (2.04-9.06)   NA  
 Unknown 11.19 (0.62-201.74)   13.35 (0.23-791.31)   NA  
HSCT  0.001   0.001   <0.001 
 No  1   1   1  
 Allogeneic  1.43 (0.84-2.44)   0.86 (0.42-1.78)   12.52 (3.8-41.18)  
 Autologous  3.68 (2.07-6.55)   4.21 (2.22-8)   6.29 (1.25-31.71)  
 Unknown 1.04 (0.35-3.08)   0.56 (0.12-2.68)   3.62 (0.44-29.52)  
Years after diagnosis  <0.001   <0.001   0.218 
 5-9 1   1   1  
 15-24 0.2 (0.12-0.34)   0.14 (0.07-0.27)   0.57 (0.23-1.44)  
  >24 0.18 (0.07-0.49)     0.12 (0.04-0.34)     0.27 (0.03-2.88)   
1
 P-value from likelihood ratio test 
2 
According to the International Classification of Childhood Cancer, 3
rd
 edition 
Abbreviations: CI = confidence interval, NA = not applicable, CNS = central nervous system 
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Figure 1. Cause-specific probability of death for different causes of death in 5-year survivors of childhood 
cancer diagnosed at age 0-14 years between 1976 and 2007 (cumulative mortality treating cause of death 
other than the one under observation as competing risks).  
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Figure 2. Cumulative mortality from all causes in 5-year survivors of childhood cancer diagnosed at age 0-14 
years according to the specific treatment area. P-value form log-rank test for trend.  
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